GSK1 N Stock Overview

Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More details

GSK1 N fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	3/6
Dividends	2/6

Rewards

Trading at 60.5% below our estimate of its fair value

Earnings are forecast to grow 19.28% per year

Risk Analysis

Shares are highly illiquid

Profit margins (8%) are lower than last year (20.5%)

Has a high level of debt

Large one-off items impacting financial results

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

GSK plc Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$23.1b

Zoetis

NYSE:ZTS

US$72.2b

Merck KGaA

XTRA:MRK

€58.5b

Chugai Pharmaceutical

TSE:4519

JP¥11.3t

Price History & Performance

Summary of share price highs, lows and changes for GSK
Historical stock prices
Current Share Price	UK£367.94
52 Week High	UK£367.94
52 Week Low	UK£357.35
Beta	0.33
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-28.31%

Recent updates

Shareholder Returns

	GSK1 N	MX Pharmaceuticals	MX Market
7D	0%	0.7%	-0.7%
1Y	n/a	-22.3%	-9.7%

Return vs Industry: Insufficient data to determine how GSK1 N performed against the MX Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GSK1 N performed against the MX Market.

Price Volatility

Is GSK1 N's price volatile compared to industry and market?
GSK1 N volatility
GSK1 N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.7%
Market Average Movement	4.2%
10% most volatile stocks in MX Market	7.2%
10% least volatile stocks in MX Market	2.7%

Stable Share Price: GSK1 N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine GSK1 N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1715	70,212	Emma Walmsley	www.gsk.com

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.

GSK plc Fundamentals Summary

How do GSK's earnings and revenue compare to its market cap?
GSK1 N fundamental statistics
Market cap	Mex$1.40t
Earnings (TTM)	Mex$64.43b
Revenue (TTM)	Mex$803.42b

21.8x

P/E Ratio

1.7x

P/S Ratio

Is GSK1 N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GSK1 N income statement (TTM)
Revenue	UK£31.31b
Cost of Revenue	UK£8.65b
Gross Profit	UK£22.67b
Other Expenses	UK£20.15b
Earnings	UK£2.51b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.62
Gross Margin	72.39%
Net Profit Margin	8.02%
Debt/Equity Ratio	119.4%

How did GSK1 N perform over the long term?

See historical performance and comparison

Dividends

4.3%

Current Dividend Yield

99%

Payout Ratio

Does GSK1 N pay a reliable dividends?

See GSK1 N dividend history and benchmarks

When do you need to buy GSK1 N by to receive an upcoming dividend?
GSK dividend dates
Ex Dividend Date	Nov 14 2024
Dividend Pay Date	Jan 09 2025
Days until Ex dividend	122 days
Days until Dividend pay date	66 days

Does GSK1 N pay a reliable dividends?

See GSK1 N dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/06 06:57
End of Day Share Price	2024/10/09 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GSK plc is covered by 64 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamla Singh	AlphaValue
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

GSK1 N Stock Overview

Rewards

Risk Analysis

GSK plc Competitors

BMV:LAB B

Mex$23.1b

NYSE:ZTS

US$72.2b

XTRA:MRK

€58.5b

TSE:4519

JP¥11.3t

Price History & Performance

Recent News & Updates

US Food and Drug Administration Accepts Depemokimab Application for the Use of D Epemokimab in Two Indications

GSK plc (LSE:GSK) announces an Equity Buyback for £2,000 million worth of its shares.

GSK plc (LSE:GSK) completed the acquisition of IDRX, Inc. from a group of shareholders.

GSK plc Announces That The Chinanational Medical Products Administration Has Accepted for Review the New Drug Application for the Use of Nucala (Mepolizumab)

GSK plc Announces Board and Committee Changes

Gsk plc Announces Approval of Penmenvy, Gsk’S 5-In-1 Meningococcal Vaccine by US FDA

Recent updates

US Food and Drug Administration Accepts Depemokimab Application for the Use of D Epemokimab in Two Indications

GSK plc (LSE:GSK) announces an Equity Buyback for £2,000 million worth of its shares.

GSK plc (LSE:GSK) completed the acquisition of IDRX, Inc. from a group of shareholders.

GSK plc Announces That The Chinanational Medical Products Administration Has Accepted for Review the New Drug Application for the Use of Nucala (Mepolizumab)

GSK plc Announces Board and Committee Changes

Gsk plc Announces Approval of Penmenvy, Gsk’S 5-In-1 Meningococcal Vaccine by US FDA

GSK plc Provides Earnings Guidance for the Full-Year of 2025; Provides Earning Guidance for 2026

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plc

GSK plc Announces Acceptancy of Depemokimab Applications for Review in China and Japan for Asthma with Type 2 Inflammation and CRSwNP

Gsk plc Announces the European Medicines Agency Accepts for Review the Regulatory Application of A Prefilled Syringe Presentation of Shingrix

GSK plc Announces the European Commission Approval to Expand the Use of Jemperli Plus Chemotherapy (Caroplatin and Paclitaxel) for First-Line Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Cancer

GSK plc to Report Q4, 2024 Results on Feb 05, 2025

GSK plc (LSE:GSK) entered into an agreement to acquire IDRX, Inc. from a group of shareholders for approximately $1.2 billion.

GSK plc (LSE:GSK) entered into an agreement to acquire IDRX, Inc. from a group of shareholders for approximately $1.2 billion.

Us Food and Drug Administration Accepts GSK Plc's Shingrix New Prefilled Syringe Presentation of Shingrix for the Prevention of Shingles (Herpes Zoster)

GSK Gets FDA Breakthrough Therapy Designation for GSK5764227

Gsk Plc's B7-H3-Targeted Antibody-Drug Conjugate, Gsk'227, Receives US Fda Breakthrough Therapy Designation in Late-Line Relapsed or Refractory Osteosarcoma

GSK plc's Nucala (Mepolizumab) Approves in China for Treatment of Adults with Chronic Rhinosinusitis with Nasal Polyps

GSK plc Announces First Trial Met Its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer

GSK plc's Jemperli (dostarlimab) Receives US FDA Breakthrough Therapy Designation for Locally Advanced dMMR/MSI-H Rectal Cancer

GSK plc Announces Results from Planned Interim Analysis of the DREAMM-7 Trial Evaluating Belantamab Mafodotin in Combination with Bortezomib Plus Dexamethasone

GSK plc Announces Blenrep Combination China Filing Acceptance

Gsk Plc's Fully Liquid Menveo Meningococcal Vaccine Approves by European Commission

Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (Pbc)

GSK plc Announces Overall Survival Results for Blenrep

Non-Executive Chairman recently bought Mex$2.6m worth of stock

Third quarter 2024 earnings released: UK£0.014 loss per share (vs UK£0.36 profit in 3Q 2023)

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

High number of new directors

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Shareholder Returns

Price Volatility

About the Company